+

WO1998005770A2 - Antisense rna with a secondary structure - Google Patents

Antisense rna with a secondary structure Download PDF

Info

Publication number
WO1998005770A2
WO1998005770A2 PCT/DE1997/001691 DE9701691W WO9805770A2 WO 1998005770 A2 WO1998005770 A2 WO 1998005770A2 DE 9701691 W DE9701691 W DE 9701691W WO 9805770 A2 WO9805770 A2 WO 9805770A2
Authority
WO
WIPO (PCT)
Prior art keywords
sense rna
expression
vector
secondary structure
pj3ω
Prior art date
Application number
PCT/DE1997/001691
Other languages
German (de)
French (fr)
Other versions
WO1998005770A3 (en
Inventor
Dieter Werner
Christof Granzow
Gaby Joswig
Karsten Rothbarth
Marie Schubert
Original Assignee
Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts filed Critical Deutches Krebsforschungszentrum Stiftung Des Öffentlichen Rechts
Priority to EP97936610A priority Critical patent/EP0918853A2/en
Publication of WO1998005770A2 publication Critical patent/WO1998005770A2/en
Publication of WO1998005770A3 publication Critical patent/WO1998005770A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C12Y203/01028—Chloramphenicol O-acetyltransferase (2.3.1.28)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Definitions

  • the present invention relates to an anti-sense RNA with a secondary structure, a combination containing it and the use of both.
  • New techniques for inhibiting gene expression often involve the use of anti-sense RNA.
  • This is an RNA that is complementary to and binds to regions of the mRNA of a gene.
  • a duplex molecule is formed that is not translated by the mRNA. An inhibition of gene expression can thus be achieved.
  • duplex molecule is often not stable, i.e. the mRNA becomes free for translation again, whereby the inhibition of gene expression is weak or does not occur at all.
  • the present invention is therefore based on the object of providing a means with which a strong inhibition of gene expression can be achieved.
  • anti-sense RNA encompasses any RNA molecule which is suitable as anti-sense RNA, ie is complementary to regions of an RNA, in particular mRNA and very particularly regulatory elements thereof, and by binding to these regions inhibits the Gene expression.
  • the anti-sense RNA can also include DNA sequences.
  • the anti-sense RNA can be present as such or in the form of a vector encoding it. Such a vector can be a common expression vector. It can be favorable if the expression of the sequence coding for the anti-sense RNA is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific promoter.
  • secondary structure encompasses any DNA and / or RNA sequence which can be present in an anti-sense RNA and which has an at least partially “hairpin” structure, ie individual base pairs are subject to refolding.
  • the secondary structure can exist within the anti-sense RNA. It can also be present at the 5 'and / or 3' end of the anti-sense RNA. If there are several secondary structures, these can be the same or different from one another.
  • Complicated palindromes such as (AGCT) n or (GAATTC) n are also preferred.
  • An anti-sense RNA according to the invention can be produced by customary methods. It is favorable to produce a double-stranded (GC) 20 EcoRI (GC) 20 sequence by oligonucleotide synthesis and to ligate this to the 5 'end of the cDNA sequence of a gene to be inhibited. The DNA molecule obtained is ligated in the 3 ' ⁇ 5' direction to the promoter of a vector. The vector obtained leads to the expression of the anti-sense RNA according to the invention.
  • GC double-stranded
  • EcoRI GC
  • An anti-sense RNA according to the invention can be introduced into cells as such or in the form of a vector encoding it.
  • the cells can be any cells, such as plant and animal, especially mammalian and very particularly human cells.
  • the cells can be inside or outside of an organism. The latter can be freshly isolated or kept in culture.
  • the anti-sense RNA can be introduced into the cells by conventional transfection techniques, such as electroporation.
  • Another object of the present invention is a combination of an anti-sense RNA according to the invention and a (ds) RNAse. This is an RNAse that can recognize and break down double-stranded RNA.
  • a (ds) RNAse is found, for example, in the yeast strain Schizosaccharomyces pombe (pad +).
  • the anti-sense RNA according to the invention can be present as such or in the form of a vector encoding it.
  • the (ds) RNAse can be present as such or in the form of a vector encoding it.
  • a vector can be a common expression vector. It can be advantageous if the expression of the sequence coding for the (ds) RNAse is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific one
  • the combination consists in the presence of a vector which codes both for the anti-sense RNA according to the invention and for the (ds) RNAse.
  • vector With regard to the vector, reference is made to the above statements.
  • the combination of an anti-sense RNA according to the invention and a (ds) RNAse can be introduced into cells.
  • the (ds) RNAse as such, i.e. as a protein, by conventional methods such as lipofection.
  • the form of a vector encoding it the
  • RNAse can be introduced by methods as they were called for the anti-sense RNA.
  • the present invention provides an anti-sense RNA and a combination containing it which cause potent inhibition of gene expression.
  • the present invention is thus widely used in molecular biology and medicine.
  • diseases in which individual proteins trigger or reinforce are, for example, diseases in which hormones play a major role, tumor diseases and viral infections, such as HIV and AIDS.
  • diseases in which hormones play a major role are, for example, diseases in which hormones play a major role, tumor diseases and viral infections, such as HIV and AIDS.
  • FIG. 1 shows the inhibition of gene expression by an anti-sense RNA according to the invention.
  • (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA.
  • (2) is the expression rate of the
  • CAT gene in the presence of an anti-sense RNA with secondary structure I.
  • (3) is the expression rate of the CAT gene in the presence of an anti-sense RNA with secondary structure II.
  • FIG. 2 shows the inhibition of gene expression by an anti-sense RNA according to the invention.
  • (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I.
  • (2) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I and a (ds) RNAse.
  • Example 1 Production of expression vectors which contain the chioramphenicolacetyl transferase (CAT) gene in the 5 ' ⁇ 3' or 3 ' ⁇ 5' direction.
  • CAT chioramphenicolacetyl transferase
  • the CAT gene was isolated from a conventional CAT vector and inserted into the "multiple cloning site" of the expression vector pJ3 ⁇ (cf. Nuclear acids res. 1 8, (1 990), 1068). In one case the insertion was in the 5 ' ⁇ 3' direction and the expression vector pJ3 ⁇ -CAT was obtained. In the other case, the insertion was carried out in the 3 '- * 5' direction and the expression vector pJ3 ⁇ -TAC was obtained.
  • Example 2 Production of expression vectors which contain the CAT gene in the 3 ' ⁇ 5' direction and a sequence coding for a secondary structure I or II.
  • AATTC- (GO 20-GAATTC- (GC) 20-GAATTC- (GC) 0-G.
  • Cloning vector pBluescript (Stratagene) was used, from which it could be removed by suitable restriction enzymes for recloning into the vector which has the CAT gene in the 3 '- * 5' direction.
  • the vector pJ3 ⁇ -TAC from Example 1 was cut in the "multiple cloning site" between the promoter and the TAC insert with suitable restriction enzymes.
  • Sequence was taken from the pBluescript vector of Example 2 (e) with the appropriate enzymes. The two nucleic acids were linked by ligation.
  • Example 3 Preparation of an expression vector which codes for a (ds) RNAse.
  • the gene (pad +) coding for a (ds) RNAse was isolated from a conventional genomic library of Schizosaccharomyces pombe by means of PCR amplification. For this purpose, primers were used which had been derived from the known sequence of the pad + gene (cf. database: embl: S78982). The pad + gene was cloned in the known vector pBluescript and confirmed by sequencing. After cloning into the usual expression vector pcDNA3 (InVitrogen), the expression vector pcDNA3-pad + was obtained.
  • Example 4 Inhibition of gene expression by an anti-sense RNA with a secondary structure
  • Ehrlich ascites tumor cells (10 7 cells / ml) were expressed with the expression vectors pJ3 ⁇ -CAT, pJ3 ⁇ -TAC, pJ3 ⁇ -TAC-sec. I or pJ3 ⁇ -TAC-sec. II transfected (see Table 1).
  • RNAse activity is produced or generated by means of the described methods.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An antisense RNA with special secondary structures is disclosed, as well as a combination of the antisense RNA and of a (ds)RNAse. The antisense RNA and its combination may be used to inhibit gene expression.

Description

Anti-Sinn-RNA mit Sekundärstruktur Anti-sense RNA with secondary structure

Die vorliegende Erfindung betrifft eine Anti-Sinn-RNA mit Sekundärstruktur, eine sie enthaltende Kombination sowie die Verwendung beider.The present invention relates to an anti-sense RNA with a secondary structure, a combination containing it and the use of both.

Neue Techniken zur Hemmung der Genexpression umfassen häufig den Einsatz von Anti-Sinn-RNA. Dies ist eine RNA, die zu Bereichen der mRNA eines Gens komplementär ist und an diese bindet. Es entsteht ein Duplexmolekül, das der Translation der mRNA entzogen ist. Damit kann eine Hemmung der Genexpression erreicht werden.New techniques for inhibiting gene expression often involve the use of anti-sense RNA. This is an RNA that is complementary to and binds to regions of the mRNA of a gene. A duplex molecule is formed that is not translated by the mRNA. An inhibition of gene expression can thus be achieved.

Es hat sich allerdings gezeigt, daß das Duplexmolekül häufig nicht stabil ist, d.h. die mRNA wird wieder frei für die Translation, wodurch die Hemmung der Genexpression schwach ist oder gar nicht eintritt.However, it has been shown that the duplex molecule is often not stable, i.e. the mRNA becomes free for translation again, whereby the inhibition of gene expression is weak or does not occur at all.

Der vorliegenden Erfindung liegt somit die Aufgabe zugrunde, ein Mittel bereitzu- stellen, mit dem eine starke Hemmung der Genexpression erzielt werden kann.The present invention is therefore based on the object of providing a means with which a strong inhibition of gene expression can be achieved.

Erfindungsgemäß wird dies durch eine Anti-Sinn-RNA mit besonderen Sekundärstrukturen erreicht.According to the invention, this is achieved by an anti-sense RNA with special secondary structures.

Mit dem Ausdruck "besonderer Sekundärdruck" ist gemeint, daß es sich nicht um eine natürlich vorkommende Sekundärstruktur handelt, sondern daß diese künstlich erzeugt worden ist.The expression "special secondary pressure" means that it is not a naturally occurring secondary structure, but that it has been created artificially.

Der Ausdruck "Anti-Sinn-RNA" umfaßt jegliches RNA-Molekül, das sich als Anti- Sinn-RNA eignet, d.h. komplementär zu Bereichen einer RNA, insbesondere mRNA und ganz besonders Regulationselementen dieser, ist und durch Bindung an diese Bereiche eine Hemmung der Genexpression bewirkt. Die Anti-Sinn-RNA kann auch DNA-Sequenzen umfassen. Ferner kann die Anti-Sinn-RNA als solche oder in Form eines sie kodierenden Vektors vorliegen. Ein solcher Vektor kann ein üblicher Expressionsvektor sein. Günstig kann es sein, wenn die Expression der für die Anti-Sinn-RNA kodierenden Sequenz unter der Kontrolle eines kon- stitutiven oder induzierbaren Promotors, wie eines Gewebe- oder Tumor-spezifischen Promotors, steht.The term “anti-sense RNA” encompasses any RNA molecule which is suitable as anti-sense RNA, ie is complementary to regions of an RNA, in particular mRNA and very particularly regulatory elements thereof, and by binding to these regions inhibits the Gene expression. The anti-sense RNA can also include DNA sequences. Furthermore, the anti-sense RNA can be present as such or in the form of a vector encoding it. Such a vector can be a common expression vector. It can be favorable if the expression of the sequence coding for the anti-sense RNA is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific promoter.

Der Ausdruck "Sekundärstruktur" umfaßt jegliche DNA- und/oder RNA-Sequenz, die in einer Anti-Sinn-RNA vorliegen kann und eine zumindest teilweise "Hair- pin"-Struktur aufweist, d.h. einzelne Basenpaare unterliegen einer Rückfaltung. Die Sekundärstruktur kann innerhalb der Anti-Sinn-RNA vorliegen. Auch kann sie am 5'- und/oder 3'-Ende der Anti-Sinn-RNA vorliegen. Liegen mehrere Sekundärstrukturen vor, können diese gleich oder verschieden voneinander sein. Vorzugsweise ist die Sekundärstruktur eine (GC)n-Palindrom-(GC)n-, <AT)n-Palindrom- (AT)n-, oder (CG)n-Palindrom-(CG)n-Sequenz, wobei es besonders bevorzugt ist, wenn n = 20 und das Palindrom eine EcoRI-Restriktionsstelle ist. Bevorzugt sind auch komplizierte Palindrome wie (AGCT)n oder (GAATTC)n.The term “secondary structure” encompasses any DNA and / or RNA sequence which can be present in an anti-sense RNA and which has an at least partially “hairpin” structure, ie individual base pairs are subject to refolding. The secondary structure can exist within the anti-sense RNA. It can also be present at the 5 'and / or 3' end of the anti-sense RNA. If there are several secondary structures, these can be the same or different from one another. The secondary structure is preferably a (GC) n -palindrome (GC) n -, <AT) n -palindrome (AT) n -, or (CG) n -palindrome (CG) n sequence, with particular preference is when n = 20 and the palindrome is an EcoRI restriction site. Complicated palindromes such as (AGCT) n or (GAATTC) n are also preferred.

Eine erfindungsgemäße Anti-Sinn-RNA kann durch übliche Verfahren hergestellt werden. Günstig ist es, durch Oligonukleotidsynthese eine doppelsträngige (GC)20-EcoRI-(GC)20-Sequenz herzustellen und diese an das 5'-Ende der cDNA- Sequenz eines zu hemmenden Gens zu ligieren. Das erhaltene DNA-Molekül wird in 3'→ 5' Richtung an den Promotor eines Vektors ligiert. Der erhaltene Vektor führt zur Expression der erfindungsgemäßen Anti-Sinn-RNA. Ergänzend wird auf Sambrook, Fritsch, Maniatis, A Laboratory Mannual, Cold Spring Harbor Labora- tory Press, 1 989, verwiesen.An anti-sense RNA according to the invention can be produced by customary methods. It is favorable to produce a double-stranded (GC) 20 EcoRI (GC) 20 sequence by oligonucleotide synthesis and to ligate this to the 5 'end of the cDNA sequence of a gene to be inhibited. The DNA molecule obtained is ligated in the 3 '→ 5' direction to the promoter of a vector. The vector obtained leads to the expression of the anti-sense RNA according to the invention. In addition, reference is made to Sambrook, Fritsch, Maniatis, A Laboratory Mannual, Cold Spring Harbor Laboratory Press, 1 989.

Eine erfindungsgemäße Anti-Sinn-RNA kann als solche oder in Form eines sie kodierenden Vektors in Zellen eingebracht werden. Die Zellen können jegliche Zellen, wie Pflanzen- und tierische, insbesondere Säugetier- und ganz besonders menschliche Zellen, sein. Die Zellen können innerhalb eines Organismus oder außerhalb eines solchen vorliegen. Letztere können frisch isoliert oder in Kultur gehalten sein. Das Einbringen der Anti-Sinn-RNA in die Zellen kann durch übliche Transfektionstechniken, wie Elektroporation, erfolgen. Ein weiterer Gegenstand der vorliegenden Erfindung ist eine Kombination aus einer erfindungsgemäßen Anti-Sinn-RNA und einer (ds)RNAse. Dies ist eine RNAse, die doppelsträngige RNA erkennen und abbauen kann. Eine (ds)RNAse findet sich z.B. in dem Hefestamm Schizosaccharomyces pombe (pad + ) . In der Kombination kann die erfindungsgemäße Anti-Sinn-RNA als solche oder in Form eines sie kodierenden Vektors vorliegen. Ebenso kann die (ds)RNAse als solche oder in Form eines sie kodierenden Vektors vorliegen. Ein solcher Vektor kann ein üblicher Expressionsvektor sein. Günstig kann es sein, wenn die Expression der für die (ds)RNAse kodierenden Sequenz unter der Kontrolle eines konstituti- ven oder induzierbaren Promotors, wie eines Gewebe- oder Tumor-spezifischenAn anti-sense RNA according to the invention can be introduced into cells as such or in the form of a vector encoding it. The cells can be any cells, such as plant and animal, especially mammalian and very particularly human cells. The cells can be inside or outside of an organism. The latter can be freshly isolated or kept in culture. The anti-sense RNA can be introduced into the cells by conventional transfection techniques, such as electroporation. Another object of the present invention is a combination of an anti-sense RNA according to the invention and a (ds) RNAse. This is an RNAse that can recognize and break down double-stranded RNA. A (ds) RNAse is found, for example, in the yeast strain Schizosaccharomyces pombe (pad +). In combination, the anti-sense RNA according to the invention can be present as such or in the form of a vector encoding it. Likewise, the (ds) RNAse can be present as such or in the form of a vector encoding it. Such a vector can be a common expression vector. It can be advantageous if the expression of the sequence coding for the (ds) RNAse is under the control of a constitutive or inducible promoter, such as a tissue- or tumor-specific one

Promotors, steht. Ferner kann es von Vorteil sein, wenn die Kombination darin besteht, daß ein Vektor vorliegt, der sowohl für die erfindungsgemäße Anti-Sinn- RNA als auch für die (ds)RNAse kodiert. Hinsichtlich des Vektors wird auf vorstehende Ausführungen verwiesen.Promoter, stands. Furthermore, it may be advantageous if the combination consists in the presence of a vector which codes both for the anti-sense RNA according to the invention and for the (ds) RNAse. With regard to the vector, reference is made to the above statements.

Die Kombination aus einer erfindungsgemäßen Anti-Sinn-RNA und einer (ds)RNAse kann in Zellen eingebracht werden. Hinsichtlich der Zellen und des Einbringens der Anti-Sinn-RNA wird auf vorstehende Ausführungen verwiesen. Die (ds)RNAse kann als solche, d.h. als Protein, durch übliche Verfahren, wie Lipofektion, eingebracht werden. In Form eines sie kodierenden Vektors kann dieThe combination of an anti-sense RNA according to the invention and a (ds) RNAse can be introduced into cells. With regard to the cells and the introduction of the anti-sense RNA, reference is made to the above statements. The (ds) RNAse as such, i.e. as a protein, by conventional methods such as lipofection. In the form of a vector encoding it, the

(ds)RNAse durch Verfahren eingebracht werden, wie sie für die Anti-Sinn-RNA genannt wurden.(ds) RNAse can be introduced by methods as they were called for the anti-sense RNA.

Die vorliegende Erfindung stellt eine Anti-Sinn-RNA und eine sie enthaltende Kombination bereit, die eine starke Hemmung der Genexpression bewirken. Die vorliegende Erfindung findet somit eine breite Anwendung in der Molekularbiologie und der Medizin. Insbesondere kann an die Diagnose und/oder Therapie von Erkrankungen gedacht werden, bei denen einzelne Proteine auslösend oder verstärkend sind. Dies sind z.B. Erkrankungen, bei denen Hormone eine große Rolle spielen, Tumorerkrankungen und virale Infektionen, wie HIV und AIDS. Kurze Beschreibung der ZeichnungThe present invention provides an anti-sense RNA and a combination containing it which cause potent inhibition of gene expression. The present invention is thus widely used in molecular biology and medicine. In particular, one can think of the diagnosis and / or therapy of diseases in which individual proteins trigger or reinforce. These are, for example, diseases in which hormones play a major role, tumor diseases and viral infections, such as HIV and AIDS. Brief description of the drawing

Fig. 1 zeigt die Hemmung der Genexpression durch eine erfindungsgemäße Anti-Sinn-RNA. ( 1 ) ist die Expressionsrate des CAT-Gens in Anwesenheit einer Anti-Sinn-RNA. (2) ist die Expressionsrate des1 shows the inhibition of gene expression by an anti-sense RNA according to the invention. (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA. (2) is the expression rate of the

CAT-Gens in Anwesenheit einer Anti-Sinn-RNA mit Sekundärstruktur I. (3) ist die Expressionsrate des CAT-Gens in Anwesenheit einer Anti-Sinn-RNA mit Sekundärstruktur II.CAT gene in the presence of an anti-sense RNA with secondary structure I. (3) is the expression rate of the CAT gene in the presence of an anti-sense RNA with secondary structure II.

Fig. 2 zeigt die Hemmung der Genexpression durch eine erfindungsgemäße Anti-Sinn-RNA. ( 1 ) ist die Expressionsrate des CAT-Gens in Anwesenheit einer Anti-Sinn-RNA mit Sekundärstruktur I. (2) ist die Expressionsrate des CAT-Gens in Anwesenheit einer Anti-Sinn-RNA mit Sekundärstruktur I und einer (ds)RNAse.2 shows the inhibition of gene expression by an anti-sense RNA according to the invention. (1) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I. (2) is the rate of expression of the CAT gene in the presence of an anti-sense RNA with secondary structure I and a (ds) RNAse.

Die Erfindung wird durch die nachfolgenden Beispiele erläutert.The invention is illustrated by the following examples.

Beispiel 1 : Herstellung von Expressions- Vektoren, die das Chioramphenicolace- tyltransferase (CAT)-Gen in 5'→ 3' bzw. 3'→ 5' Richtung enthalten.Example 1: Production of expression vectors which contain the chioramphenicolacetyl transferase (CAT) gene in the 5 '→ 3' or 3 '→ 5' direction.

Das CAT-Gen wurde aus einem üblichen CAT-Vektor isoliert und in die "multiple cloning site" des Expressionsvektors pJ3Ω (vgl. Nu- cleic acids res. 1 8, ( 1 990), 1068) inseriert. In einem Fall erfolgte die Insertion in 5'→3' Richtung und es wurde der Expressionsvektor pJ3Ω-CAT erhalten. Im anderen Fall erfolgte die Insertion in 3'-*5' Richtung und es wurde der Expressionsvektor pJ3Ω-TAC erhalten. Beispiel 2: Herstellung von Expressionsvektoren, die das CAT-Gen in 3'→ 5' Richtung und eine für eine Sekundärstruktur I bzw. II kodierende Sequenz enthalten.The CAT gene was isolated from a conventional CAT vector and inserted into the "multiple cloning site" of the expression vector pJ3Ω (cf. Nuclear acids res. 1 8, (1 990), 1068). In one case the insertion was in the 5 '→ 3' direction and the expression vector pJ3Ω-CAT was obtained. In the other case, the insertion was carried out in the 3 '- * 5' direction and the expression vector pJ3Ω-TAC was obtained. Example 2: Production of expression vectors which contain the CAT gene in the 3 '→ 5' direction and a sequence coding for a secondary structure I or II.

(A) Expressionsvektor mit einer (GC)20-EcoRI-{GC)20-Sequeπz am 5'-Ende des CAT-Gens (Sekundärstruktur I)(A) Expression vector with a (GC) 20 -EcoRI- (GC) 20 sequence at the 5 'end of the CAT gene (secondary structure I)

1 . Herstellung einer (GC)20-EcoRI-(GC)20-Sequenz.1 . Preparation of a (GC) 20 EcoRI (GC) 20 sequence.

(a) Mittels eines automatischen Synthese-Geräts (Oligonukleotid-(a) Using an automatic synthesis device (oligonucleotide

Synthesizer) wurden 2 Oligodesoxynukleotide hergestellt:2 oligodeoxynucleotides were produced:

AATTC- (GC) 20-G undAATTC- (GC) 20-G and

G- (GC ) 2θ-CTTAAG- (GC) 2 θ-CTTAA

(b) Die beiden Oligodesoxynukleotide wurden im Verhältnis 1 : 1 gemischt, auf 90°C erhitzt, danach langsam unter "annea- Iing"-Bedingungen auf Raumtemperatur abgekühlt. Dabei ent- stand ein DNA Dopplestrang folgender Struktur:(b) The two oligodeoxynucleotides were mixed in a ratio of 1: 1, heated to 90 ° C., then slowly cooled to room temperature under "annealing" conditions. This resulted in a DNA double strand of the following structure:

AATTC- (GC ) 20-G * * * *AATTC- (GC) 20-G * * * *

G- ( GC ) 20-CTTAAG- (GC) 20-CTTAA

(c) Unter Ligationsbedingungen entstanden Vielfache der in (b) beschriebenen DNA(c) Multiples of the DNA described in (b) were generated under ligation conditions

AATTC- (GO 20-GAATTC- (GC ) 20-GAATTC- (GC ) 0-G .AATTC- (GO 20-GAATTC- (GC) 20-GAATTC- (GC) 0-G.

* ** ****** ** ***** ** →,* ** ****** ** ***** ** →,

G- (GC) 20-CTTAAG- (GC) 20-CTTAAG- (GC) 20-CTTAA..G- ( GC ) 20-CTTAAG- (GC) 20-CTTAAG- (GC) 20-CTTAA ..

(d) Die Ligationsprodukte wurden durch Gelelektrophorese nach Größe aufgetrennt und eine Sequenz, bestehend aus Dimeren, wurde aus dem Gel eluiert und mittels Polynukleotidkinase /ATP phosphoryliert.(d) The ligation products were refined by gel electrophoresis Size separated and a sequence consisting of dimers was eluted from the gel and phosphorylated using polynucleotide kinase / ATP.

AATTC- (GC) 0-GAATTC- (GC) 20-G-PAATTC- (GC) 0-GAATTC- (GC) 20-G-P

* * * * * * * * * * * ** * * * * * * * * * * *

P-G- ( GC ) 20-CTTAAG- (GC) 20"CPG- (GC) 20-CTTAAG- (GC) 2 0 "C

(e) Diese Sequenz wurde zunächst in die EcoRI-Stelle des üblichen(e) This sequence was first inserted into the EcoRI site of the usual

Klonierungsvektors pBluescript (Stratagene) eingesetzt, aus dem sie durch geeignete Restriktionsenzyme zur Umklonierung in- den Vektor, der das CAT-Gen in 3'-* 5' Richtung aufweist, entnommen werden konnte.Cloning vector pBluescript (Stratagene) was used, from which it could be removed by suitable restriction enzymes for recloning into the vector which has the CAT gene in the 3 '- * 5' direction.

2. Einbau der {GC)2o-EcoRI-(GC)2o) Sequenz in den Vektor, der das CAT- Gen in 3'→ 5' Richtung aufweist.2. Incorporation of the {GC) 2 o-EcoRI (GC) 2 o) sequence into the vector which has the CAT gene in the 3 '→ 5' direction.

Der Vektor pJ3Ω-TAC von Beispiel 1 wurde in der "multiple cloning site" zwischen dem Promotor und der TAC-Insertion mit geeigneten Restriktionsenzymen geschnitten. Die (GC)20-EcoRI-(GC)20| Sequenz wurde mit den entsprechenden Enzymen aus dem pBluescript-Vektor von Beispiel 2(e) entnommen. Die beiden Nukleinsäuren wurden per Ligation verbunden. Es wurde der Expressionsvektor pJ3Ω-TAC-Sek. I erhalten.The vector pJ3Ω-TAC from Example 1 was cut in the "multiple cloning site" between the promoter and the TAC insert with suitable restriction enzymes. The (GC) 20 -EcoRI- (GC) 20 | Sequence was taken from the pBluescript vector of Example 2 (e) with the appropriate enzymes. The two nucleic acids were linked by ligation. The expression vector pJ3Ω-TAC-sec. I received.

(B) Expressionsvektor mit einer (GC)20-EcoRI-(GC,20-Sequenz am 3'-Ende des CAT-Gens (Sekundärstruktur II).(B) Expression vector with a (GC) 20 EcoRI (GC, 20 sequence at the 3 'end of the CAT gene (secondary structure II).

Die unter Beispiel 2 (A) hergestellte (GC)20-EcoRI-(GC)20-Sequenz wurde in den Vektor pJ3Ω-TAC am 3'-Ende des TAC-Gens eingesetzt. Es wurde der Expressionsvektor pJ3Ω-TAC-Sek.ll erhalten. Beispiel 3: Herstellung eines Expressionsvektors, der für eine (ds) RNAse kodiert.The (GC) 20 EcoRI (GC) 20 sequence prepared in Example 2 (A) was inserted into the vector pJ3Ω-TAC at the 3 'end of the TAC gene. The expression vector pJ3Ω-TAC-Sek.ll was obtained. Example 3: Preparation of an expression vector which codes for a (ds) RNAse.

Aus einer üblichen genomischen Bibliothek von Schizosaccharomy- ces pombe wurde mittels einer PCR-Amplifikation das für eine (ds)RNAse kodierende Gen (pad + ) isoliert. Hierzu wurden Primer verwendet, die aus der bekannten Sequenz des Gens pad + (vgl. Datenbank: embl: S78982) abgeleitet worden waren. Das Gen pad + wurde in dem bekannten Vektor pBluescript kloniert und durch Sequenzierung bestätigt. Nach Umklonierung in den üblichen Expressionsvektor pcDNA3 (InVitrogen) wurde der Expressionsvektor pcDNA3-pad + erhalten.The gene (pad +) coding for a (ds) RNAse was isolated from a conventional genomic library of Schizosaccharomyces pombe by means of PCR amplification. For this purpose, primers were used which had been derived from the known sequence of the pad + gene (cf. database: embl: S78982). The pad + gene was cloned in the known vector pBluescript and confirmed by sequencing. After cloning into the usual expression vector pcDNA3 (InVitrogen), the expression vector pcDNA3-pad + was obtained.

Beispiel 4: Hemmung der Genexpression durch eine Anti-Sinn-RNA mit SekundärstrukturExample 4: Inhibition of gene expression by an anti-sense RNA with a secondary structure

(a) Ehrlich Ascites Tumorzellen ( 107 Zellen/ml) wurden mit den Expressionsvektoren pJ3Ω-CAT, pJ3Ω-TAC, pJ3Ω-TAC-Sek. I bzw. pJ3Ω-TAC-Sek. II transfiziert (vgl. Tabelle 1 ) . Die Transfektion wurde mittels Elektroporation (366V/950μF/Ele- ktrodenabstand D = 4mm) durchgeführt. 24 h nach Transfektion wurden die Zellen geerntet, lysiert und Aliquote mit radioaktiv markiertem Chloramphenicol inkubiert. Es wurde die Konversionsrate (in Ac-, Di-Ac-Chloramphenicol) nach DC durch Messung der Radioaktivität bestimmt. (a) Ehrlich ascites tumor cells (10 7 cells / ml) were expressed with the expression vectors pJ3Ω-CAT, pJ3Ω-TAC, pJ3Ω-TAC-sec. I or pJ3Ω-TAC-sec. II transfected (see Table 1). The transfection was carried out by means of electroporation (366V / 950μF / electrode distance D = 4mm). 24 hours after transfection, the cells were harvested, lysed and aliquots were incubated with radioactively labeled chloramphenicol. The conversion rate (in Ac-, Di-Ac-Chloramphenicol) after DC was determined by measuring the radioactivity.

Tabelle 1 :Table 1 :

pJ3Ω-CAT 3//g 3/yg 3/ gpJ3Ω-CAT 3 // g 3 / yg 3 / g

Figure imgf000010_0001
Figure imgf000010_0001

pJ3Ω-TAC-Sek. I - 7,5/ygpJ3Ω TAC sec. I - 7.5 / yg

pJ3Ω-TAC-Sek. II - - 7,5μgpJ3Ω TAC sec. II - - 7.5μg

Aus Fig. 1 geht hervor, daß durch Transfektion von pJ3Ω-TAC-Sek. I bzw. pJ3Ω-TAC-Sek. II (vgl. Fig. 1 , (2), (3) eine stärkere Hemmung der Expression des CAT-Gens erreicht werden kann, als wenn ρJ3Ω-TAC (vgl. Fig. 1 , ( 1 ) verwendet wird.From Fig. 1 it appears that by transfection of pJ3Ω-TAC-sec. I or pJ3Ω-TAC-sec. II (cf. FIG. 1, (2), (3) a greater inhibition of the expression of the CAT gene can be achieved than if ρJ3Ω-TAC (cf. FIG. 1, (1) is used.

(b) Ehrlich Ascites Tumorzellen ( 107 Zellen/ml) wurden mit den Expressionsvektoren pJ3Ω-CAT, pJ3Ω-TAC-Sek. I bzw. pcDNA3-pad + tranfiziert (vgl. Tabelle 2). Die Transfektionsbedingungen waren wie in Beispiel 4 (a) beschrieben.(b) Ehrlich ascites tumor cells (10 7 cells / ml) were expressed with the expression vectors pJ3Ω-CAT, pJ3Ω-TAC-Sek. I or pcDNA3-pad + transfected (see Table 2). The transfection conditions were as described in Example 4 (a).

Tabelle 2:Table 2:

1 2 pJ3Ω-CAT 5 vg 5μg pJ3Ω-TAC-Sek. 10/yg 10/yg pcDNA3-pad + - 10/yg1 2 pJ3Ω-CAT 5 vg 5μg pJ3Ω-TAC-sec. 10 / yg 10 / yg pcDNA3-pad + - 10 / yg

Aus Fig. 2 geht hervor, daß durch Kotransfektion von pJ3Ω-TAC-Sek. I mit pcDNA3-pad + (vgl. Fig. 2 (2)) eine stärkere Hemmung der Expres- sion von CAT erhalten wird, als wenn pJ3Ω-TAC-Sek. I (vgl. Fig. 2, ( 1 ) alleine verwendet wird. Somit wird deutlich, daß eine Anti-Sinn-RNA mit Sekundärstruktur eine größere Hemmwirkung auf die Genexpression hat als eine Anti-Sinn-RNA ohne Sekundärstruktur. Ferner wird deutlich, daß die Hemmwirkung der Anti-Sinn-RNA mit Sekundärstruktur noch gesteigert werden kann, wenn zusätzlich zu gegebenenfalls natürlich vorhandenen (ds)RNAsen eineFrom Fig. 2 it appears that by co-transfection of pJ3Ω-TAC-sec. I with pcDNA3-pad + (see FIG. 2 (2)) a stronger inhibition of the expression of CAT is obtained than if pJ3Ω-TAC-sec. I (see Fig. 2, (1) is used alone. It is thus clear that an anti-sense RNA with a secondary structure has a greater inhibitory effect on gene expression than an anti-sense RNA without a secondary structure. It is also clear that the inhibitory effect of the anti-sense RNA with a secondary structure can be increased if, in addition to any naturally present (ds) RNAses

(ds)RNAse-Aktivität mittels der beschriebenen Verfahren hervorgerufen bzw. erzeugt wird. (ds) RNAse activity is produced or generated by means of the described methods.

Claims

Patentansprüche claims 1 . Anti-Sinn-RNA mit besonderen Sekundärstrukturen.1 . Anti-sense RNA with special secondary structures. 2. Anti-Sinn-RNA nach Anspruch 1 , dadurch gekennzeichnet, daß die Sekundärstruktur am 5'- und/oder 3'-Ende der Anti-Sinn-RNA geschaffen wor- den ist.2. Anti-sense RNA according to claim 1, characterized in that the secondary structure at the 5 'and / or 3' end of the anti-sense RNA has been created. 3. Anti-Sinn-RNA nach Anspruch 1 oder 2, dadurch gekennzeichnet, daß die Sekundärstruktur eine (GOn-PalindrorrHGC),,- oder (CG)n-Palindrom-(CG)n- Sequenz ist.3. Anti-sense RNA according to claim 1 or 2, characterized in that the secondary structure is a (GO n -PalindrorrHGC) ,, - or (CG) n -Palindrome- (CG) n - sequence. 4. Anti-Sinn-RNA nach Anspruch 3, dadurch gekennzeichnet, daß n = 20 und das Palindrom eine EcoRI-Restriktionsstelle ist.4. Anti-sense RNA according to claim 3, characterized in that n = 20 and the palindrome is an EcoRI restriction site. 5. Anti-Sinn-RNA nach einem der Ansprüche 1 - 4, dadurch gekennzeichnet, daß die Anti-Sinn-RNA durch einen Vektor kodiert ist.5. Anti-sense RNA according to one of claims 1-4, characterized in that the anti-sense RNA is encoded by a vector. 6. Kombination, umfassend die Anti-Sinn-RNA nach einem der Ansprüche 1 - 5 und eine (ds)RNAse.6. Combination comprising the anti-sense RNA according to any one of claims 1-5 and a (ds) RNAse. 7. Kombination nach Anspruch 6, dadurch gekennzeichnet, daß die Anti-7. Combination according to claim 6, characterized in that the anti Sinn-RNA und die (ds)RNAse durch einen oder mehrere Vektoren kodiert sind.Sense RNA and the (ds) RNAse are encoded by one or more vectors. 8. Verwendung der Anti-Sinn-RNA nach einem der Ansprüche 1 -5 und der Kombination nach Anspruch 6 oder 7 zur Hemmung der Genexpression. 8. Use of the anti-sense RNA according to one of claims 1 -5 and the combination according to claim 6 or 7 for inhibiting gene expression.
PCT/DE1997/001691 1996-08-07 1997-08-05 Antisense rna with a secondary structure WO1998005770A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP97936610A EP0918853A2 (en) 1996-08-07 1997-08-05 Antisense rna with a secondary structure

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1996131919 DE19631919C2 (en) 1996-08-07 1996-08-07 Anti-sense RNA with secondary structure
DE19631919.6 1996-08-07

Publications (2)

Publication Number Publication Date
WO1998005770A2 true WO1998005770A2 (en) 1998-02-12
WO1998005770A3 WO1998005770A3 (en) 1998-03-26

Family

ID=7802056

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/001691 WO1998005770A2 (en) 1996-08-07 1997-08-05 Antisense rna with a secondary structure

Country Status (3)

Country Link
EP (1) EP0918853A2 (en)
DE (1) DE19631919C2 (en)
WO (1) WO1998005770A2 (en)

Cited By (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053050A1 (en) * 1998-04-08 1999-10-21 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
WO2000044895A1 (en) * 1999-01-30 2000-08-03 Roland Kreutzer Method and medicament for inhibiting the expression of a defined gene
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
WO2001036646A1 (en) * 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibiting gene expression with dsrna
WO2003035868A1 (en) * 2001-10-26 2003-05-01 Ribopharma Ag Medicament that increases the effectiveness of a drug that induces receptor-mediated apoptosis in tumor cells
WO2002055692A3 (en) * 2001-01-09 2003-06-12 Ribopharma Ag Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
WO2002055693A3 (en) * 2001-01-09 2003-07-17 Ribopharma Ag Method for inhibiting the expression of a target gene
EP1445321A1 (en) 2002-12-18 2004-08-11 Monsanto Technology LLC Maize embryo-specific promoter compositions and methods for use thereof
WO2005110068A2 (en) 2004-04-09 2005-11-24 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
EP1621632A1 (en) 2004-07-31 2006-02-01 Monsanto Technology, LLC Genes and uses for plant improvement
EP1575977A4 (en) * 2002-12-23 2006-04-26 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods of using the same
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7148336B2 (en) 1999-08-26 2006-12-12 Calgene Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acid levels
WO2006133983A1 (en) 2005-04-19 2006-12-21 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
WO2007095469A2 (en) 2006-02-10 2007-08-23 Monsanto Technology Llc Identification and use of target genes for control of plant parasitic nematodes
WO2008099013A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
US7576262B2 (en) 2002-03-14 2009-08-18 Commonwealth Scientific And Industrial Research Organization Modified gene-silencing RNA and uses thereof
US7601888B2 (en) 2002-03-21 2009-10-13 Monsanto Technology L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
AU2008202208B2 (en) * 1999-01-30 2009-10-29 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
EP2116606A1 (en) 2003-03-28 2009-11-11 Monsanto Technology, LLC Novel plant promoters for use in early seed development
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2010123904A1 (en) 2009-04-20 2010-10-28 Monsanto Technology Llc Multiple virus resistance in plants
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
EP2269444A2 (en) 2005-09-16 2011-01-05 deVGen N.V. DSRNA as insect control agent
EP2275562A2 (en) 2005-09-16 2011-01-19 deVGen N.V. Transgenic plant-based methods for plant insect pests using RNAi
EP2292773A1 (en) 2004-03-25 2011-03-09 Monsanto Technology LLC Genes and uses for plant improvement
US7943819B2 (en) 2005-09-16 2011-05-17 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
US8053419B2 (en) 1998-03-20 2011-11-08 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US8114980B2 (en) 1998-07-03 2012-02-14 Devgen Nv Characterisation of gene function using double stranded RNA inhibition
EP2426206A2 (en) 2006-02-13 2012-03-07 Monsanto Technology LLC Selecting and stablizing dsRNA constructs
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US8168774B2 (en) 1998-03-20 2012-05-01 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US8183217B2 (en) 1999-08-13 2012-05-22 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
WO2012092544A2 (en) 2010-12-30 2012-07-05 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2489726A2 (en) 2005-01-12 2012-08-22 Monsanto Technology LLC Genes and uses for plant improvement
US8273868B2 (en) 2001-10-12 2012-09-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
US8299042B2 (en) 2002-04-26 2012-10-30 Alnylam Pharmaceuticals, Inc. Methods and compositions for silencing genes without inducing toxicity
US8329989B2 (en) 2008-09-29 2012-12-11 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8394628B2 (en) 2000-03-30 2013-03-12 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
US8895805B2 (en) 2006-12-04 2014-11-25 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Method for modifying insect resistance of plants by utilizing RNAi technique
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
WO2015095750A1 (en) 2013-12-20 2015-06-25 Dow Agrosciences Llc Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests
WO2015095774A1 (en) 2013-12-20 2015-06-25 Dow Agrosciences Llc Ras opposite (rop) and related nucleic acid molecules that confer resistance to coleopteran and/or hemipteran pests
US9074213B2 (en) 2001-01-09 2015-07-07 Alnylam Pharmacuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US9102939B2 (en) 1997-12-23 2015-08-11 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
WO2015171784A1 (en) 2014-05-07 2015-11-12 Dow Agrosciences Llc Dre4 nucleic acid molecules that confer resistance to coleopteran pests
EP3037432A1 (en) 2014-12-22 2016-06-29 Dow AgroSciences LLC Nucampholin nucleic acid molecules to control coleopteran insect pests
US9441239B2 (en) 1998-04-08 2016-09-13 Commonwealth Scientific & Industrial Research Organisation Methods and means for obtaining modified phenotypes
EP3067424A1 (en) 2015-03-13 2016-09-14 Dow AgroSciences LLC Rna polymerase i1 nucleic acid molecules to control insect pests
WO2016165729A1 (en) 2015-04-13 2016-10-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel aflatoxin and fungal infection control methods
WO2016196247A1 (en) 2015-05-29 2016-12-08 Dow Agrosciences Llc Spt5 nucleic acid molecules to control insect pests
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
US9765351B2 (en) 2006-02-13 2017-09-19 Monsanto Technology Llc Modified gene silencing
WO2018089237A1 (en) 2016-11-10 2018-05-17 Dow Agrosciences Llc Cytochrome b (cytb) nucleic acid molecules that control pathogens
EP3339440A1 (en) 2010-12-30 2018-06-27 Dow AgroSciences LLC Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
EP3342780A1 (en) 2016-12-30 2018-07-04 Dow AgroSciences LLC Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
EP3354735A1 (en) 2010-12-30 2018-08-01 Dow AgroSciences LLC Nucleic acid molecules that target the rho1 small gtp-binding protein and confer resistance to coleopteran pests
EP3375878A1 (en) 2010-12-30 2018-09-19 Dow AgroSciences LLC Nucleic acid molecules that target the vacuolar atphase h subunit and confer resistance to coleopteran pests
US10329581B2 (en) 2015-12-18 2019-06-25 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
US10344298B2 (en) 2015-10-12 2019-07-09 Dow Agrosciences Llc WUPA nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
EP3719129A1 (en) 2014-03-12 2020-10-07 The University of Sydney Rna production in higher plants
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
CA2369944A1 (en) 2001-01-31 2002-07-31 Nucleonics Inc. Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2675803B1 (en) * 1991-04-25 1996-09-06 Genset Sa CLOSED, ANTISENSE AND SENSE OLIGONUCLEOTIDES AND THEIR APPLICATIONS.
ES2169040T3 (en) * 1992-04-17 2002-07-01 Kirin Brewery RESISTANT PLANT TO TWO OR MORE VIRUSES AND PREPARATION OF THE SAME.
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
GB2273932A (en) * 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
FR2703053B1 (en) * 1993-03-26 1995-06-16 Genset Sa STAPLE AND SEMI-STAPLE OLIGONUCLEOTIDES, PREPARATION METHOD AND APPLICATIONS.
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom

Cited By (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9102939B2 (en) 1997-12-23 2015-08-11 The Carnegie Institution Of Washington Genetic inhibition by double-stranded RNA
US8168774B2 (en) 1998-03-20 2012-05-01 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US8053419B2 (en) 1998-03-20 2011-11-08 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
US9963698B2 (en) 1998-03-20 2018-05-08 Commonwealth Scientific And Industrial Research Organisation Control of gene expression
US9029527B2 (en) 1998-03-20 2015-05-12 Commonwealth Scientific And Industrial Research Organisation Synthetic genes and genetic constructs
EP2267138A2 (en) 1998-04-08 2010-12-29 Commonwealth Scientific and Industrial Research Organization Methods and means for obtaining modified phenotypes
EP2267139A2 (en) 1998-04-08 2010-12-29 Commonwealth Scientific and Industrial Research Organization Methods and means for obtaining modified phenotypes
WO1999053050A1 (en) * 1998-04-08 1999-10-21 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
EP3214177A2 (en) 1998-04-08 2017-09-06 Commonwealth Scientific and Industrial Research Organisation Methods and means for obtaining modified phenotypes
US8598332B1 (en) 1998-04-08 2013-12-03 Bayer Cropscience N.V. Methods and means for obtaining modified phenotypes
US9441239B2 (en) 1998-04-08 2016-09-13 Commonwealth Scientific & Industrial Research Organisation Methods and means for obtaining modified phenotypes
US8114980B2 (en) 1998-07-03 2012-02-14 Devgen Nv Characterisation of gene function using double stranded RNA inhibition
CZ304897B6 (en) * 1998-07-03 2015-01-07 Devgen N. V. Method of delivering double-stranded RNA or DNA capable of producing double-stranded RNA and non-therapeutic use of bacterial or yeas cell
EP1798285A1 (en) * 1999-01-30 2007-06-20 Alnylam Europe AG Methods and medicament for inhibition the expression of a defined gene
US8202980B2 (en) 1999-01-30 2012-06-19 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
WO2000044895A1 (en) * 1999-01-30 2000-08-03 Roland Kreutzer Method and medicament for inhibiting the expression of a defined gene
EP3018207A1 (en) * 1999-01-30 2016-05-11 Alnylam Europe AG Oligoribonucucleotide for inhibiting the expression of a predefined gene
EP2363479A1 (en) * 1999-01-30 2011-09-07 Alnylam Europe AG Oligoribonucucleotide for inhibiting the expression of a predefined gene
US9902955B2 (en) 1999-01-30 2018-02-27 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
EP1214945A3 (en) * 1999-01-30 2002-09-04 Ribopharma AG Method and medicament for inhibiting the expression of a defined gene
US9133454B2 (en) 1999-01-30 2015-09-15 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a given gene
AU2005201044B2 (en) * 1999-01-30 2008-05-29 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
EP1550719A1 (en) * 1999-01-30 2005-07-06 Alnylam Europe AG Methods and medicament for inhibition the expression of a defined gene
AU2008202208B2 (en) * 1999-01-30 2009-10-29 Alnylam Pharmaceuticals, Inc. Method and medicament for inhibiting the expression of a defined gene
EP2363478A1 (en) 1999-04-21 2011-09-07 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000063364A3 (en) * 1999-04-21 2001-01-11 American Home Prod Methods and compositions for inhibiting the function of polynucleotide sequences
WO2000063364A2 (en) 1999-04-21 2000-10-26 American Home Products Corporation Methods and compositions for inhibiting the function of polynucleotide sequences
US10190127B2 (en) 1999-08-13 2019-01-29 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US8183217B2 (en) 1999-08-13 2012-05-22 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US9708621B2 (en) 1999-08-13 2017-07-18 Commonwealth Scientific And Industrial Research Organisation Methods and means for obtaining modified phenotypes
US7563949B2 (en) 1999-08-26 2009-07-21 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7531718B2 (en) 1999-08-26 2009-05-12 Monsanto Technology, L.L.C. Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7067722B2 (en) 1999-08-26 2006-06-27 Monsanto Technology Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7256329B2 (en) 1999-08-26 2007-08-14 Calgene Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US8097778B2 (en) 1999-08-26 2012-01-17 Monsanto Company Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acids
US7148336B2 (en) 1999-08-26 2006-12-12 Calgene Llc Nucleic acid sequences and methods of use for the production of plants with modified polyunsaturated fatty acid levels
WO2001036646A1 (en) * 1999-11-19 2001-05-25 Cancer Research Ventures Limited Inhibiting gene expression with dsrna
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8394628B2 (en) 2000-03-30 2013-03-12 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US10472625B2 (en) 2000-03-30 2019-11-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US8552171B2 (en) 2000-03-30 2013-10-08 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8420391B2 (en) 2000-03-30 2013-04-16 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8632997B2 (en) 2000-03-30 2014-01-21 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US8742092B2 (en) 2000-03-30 2014-06-03 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US9193753B2 (en) 2000-03-30 2015-11-24 University Of Massachusetts RNA sequence-specific mediators of RNA interference
US9012621B2 (en) 2000-03-30 2015-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US9012138B2 (en) 2000-03-30 2015-04-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US8790922B2 (en) 2000-03-30 2014-07-29 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA sequence-specific mediators of RNA interference
US10633656B2 (en) 2000-12-01 2020-04-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. RNA interference mediating small RNA molecules
US8445237B2 (en) 2000-12-01 2013-05-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8329463B2 (en) 2000-12-01 2012-12-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8362231B2 (en) 2000-12-01 2013-01-29 Max-Planck-Gesellschaft zur Föderung der Wissenschaften E.V. RNA interference mediating small RNA molecules
US8796016B2 (en) 2000-12-01 2014-08-05 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8853384B2 (en) 2000-12-01 2014-10-07 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8895718B2 (en) 2000-12-01 2014-11-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8895721B2 (en) 2000-12-01 2014-11-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8933044B2 (en) 2000-12-01 2015-01-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8993745B2 (en) 2000-12-01 2015-03-31 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8372968B2 (en) 2000-12-01 2013-02-12 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8778902B2 (en) 2000-12-01 2014-07-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
US8765930B2 (en) 2000-12-01 2014-07-01 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediating small RNA molecules
EP2365075A1 (en) * 2001-01-09 2011-09-14 Alnylam Europe AG Method for inhibiting the expression of a target gene and medicine for treating a tumour illness
US7473525B2 (en) 2001-01-09 2009-01-06 Alnylam Europe Ag Compositions and methods for inhibiting expression of anti-apoptotic genes
EP2213736A3 (en) * 2001-01-09 2010-09-01 Alnylam Europe AG Method for inhibiting the expression of a target gene and medicine for treating a tumour illness
WO2002055692A3 (en) * 2001-01-09 2003-06-12 Ribopharma Ag Method for inhibiting the expression of a target gene and medicament for treating a tumor disease
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
WO2002055693A3 (en) * 2001-01-09 2003-07-17 Ribopharma Ag Method for inhibiting the expression of a target gene
US9074213B2 (en) 2001-01-09 2015-07-07 Alnylam Pharmacuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US7868160B2 (en) 2001-01-09 2011-01-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7423142B2 (en) 2001-01-09 2008-09-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7612194B2 (en) 2001-07-24 2009-11-03 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera LeConte and uses thereof
US8614370B2 (en) 2001-07-24 2013-12-24 Monsanto Technology Llc Nucleic acid sequences from Diabrotica virgifera virgifera leconte and uses thereof
US8273868B2 (en) 2001-10-12 2012-09-25 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting viral replication
WO2003035868A1 (en) * 2001-10-26 2003-05-01 Ribopharma Ag Medicament that increases the effectiveness of a drug that induces receptor-mediated apoptosis in tumor cells
US7576262B2 (en) 2002-03-14 2009-08-18 Commonwealth Scientific And Industrial Research Organization Modified gene-silencing RNA and uses thereof
US7566813B2 (en) 2002-03-21 2009-07-28 Monsanto Technology, L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
US8802922B2 (en) 2002-03-21 2014-08-12 Monsanto Technology Llc Nucleic acid constructs and methods for producing altered seed oil compositions
US7601888B2 (en) 2002-03-21 2009-10-13 Monsanto Technology L.L.C. Nucleic acid constructs and methods for producing altered seed oil compositions
US10280430B2 (en) 2002-03-21 2019-05-07 Monsanto Technology Llc Nucleic acid constructs and methods for producing altered seed oil compositions
US8299042B2 (en) 2002-04-26 2012-10-30 Alnylam Pharmaceuticals, Inc. Methods and compositions for silencing genes without inducing toxicity
US7166771B2 (en) 2002-06-21 2007-01-23 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
US9758784B1 (en) 2002-08-05 2017-09-12 Silence Therapeutics Gmbh Interfering RNA molecules
US9695423B2 (en) 2002-08-05 2017-07-04 Silence Therapeutics Gmbh Interfering RNA molecules
US9790501B2 (en) 2002-08-05 2017-10-17 Silence Therapeutics Gmbh Interfering RNA molecules
US9222092B2 (en) 2002-08-05 2015-12-29 Silence Therapeutics Gmbh Interfering RNA molecules
US10266829B2 (en) 2002-08-05 2019-04-23 Silence Therapeutics Gmbh Interfering RNA molecules
US10774332B2 (en) 2002-08-05 2020-09-15 Silence Therapeutics Gmbh Interfering RNA molecules
US8933215B2 (en) 2002-08-05 2015-01-13 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US11578328B2 (en) 2002-08-05 2023-02-14 Silence Therapeutics Gmbh Interfering RNA molecules
US10323246B2 (en) 2002-08-05 2019-06-18 Silence Therapeutics Gmbh Interfering RNA molecules
US8324370B2 (en) 2002-08-05 2012-12-04 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US7452987B2 (en) 2002-08-05 2008-11-18 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US7893245B2 (en) 2002-08-05 2011-02-22 Silence Therapeutics Aktiengesellschaft (Ag) Interfering RNA molecules
US9783802B2 (en) 2002-08-05 2017-10-10 Silence Therapeutics Gmbh Interfering RNA molecules
US10329568B2 (en) 2002-08-05 2019-06-25 Silence Therapeutics Gmbh Interfering RNA molecules
US9790505B2 (en) 2002-08-05 2017-10-17 Silence Therapeutics Gmbh Interfering RNA molecules
EP1445321A1 (en) 2002-12-18 2004-08-11 Monsanto Technology LLC Maize embryo-specific promoter compositions and methods for use thereof
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7745606B2 (en) 2002-12-23 2010-06-29 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US11312965B2 (en) 2002-12-23 2022-04-26 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US10196643B2 (en) 2002-12-23 2019-02-05 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
CN101693890B (en) * 2002-12-23 2012-09-05 戴纳伐克斯技术股份有限公司 Immunostimulatory sequence oligonucleotides and methods of using the same
AU2003297483B2 (en) * 2002-12-23 2010-11-18 Trisalus Life Sciences, Inc. Immunostimulatory sequence oligonucleotides and methods of using the same
EP1575977A4 (en) * 2002-12-23 2006-04-26 Dynavax Tech Corp Immunostimulatory sequence oligonucleotides and methods of using the same
EP2116607A1 (en) 2003-03-28 2009-11-11 Monsanto Technology, LLC Novel plant promoters for use in early seed development
EP2116606A1 (en) 2003-03-28 2009-11-11 Monsanto Technology, LLC Novel plant promoters for use in early seed development
US7795504B2 (en) 2003-09-24 2010-09-14 Monsanto Technology Llc Coordinated decrease and increase of gene expression of more than one gene using transgenic constructs
EP2292773A1 (en) 2004-03-25 2011-03-09 Monsanto Technology LLC Genes and uses for plant improvement
US8946510B2 (en) 2004-04-09 2015-02-03 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
US11492638B2 (en) 2004-04-09 2022-11-08 Monsanto Technology, Llc Compositions and methods for control of insect infestations in plants
US9340797B2 (en) 2004-04-09 2016-05-17 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
US12077770B2 (en) 2004-04-09 2024-09-03 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
US10167484B2 (en) 2004-04-09 2019-01-01 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
EP2402441A1 (en) 2004-04-09 2012-01-04 Monsanto Technology, LLC Compositions and methods for control of insect infestations in plants
WO2005110068A2 (en) 2004-04-09 2005-11-24 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
EP2308971A1 (en) 2004-04-09 2011-04-13 Monsanto Technology LLC Compositions and methods for control of insect infestations in plants
US11685930B2 (en) 2004-04-09 2023-06-27 Monsanto Technology, Llc Compositions and methods for control of insect infestations in plants
US9238822B2 (en) 2004-04-09 2016-01-19 Monsanto Technology Llc Compositions and methods for control of insect infestations in plants
EP1621632A1 (en) 2004-07-31 2006-02-01 Monsanto Technology, LLC Genes and uses for plant improvement
EP2295582A2 (en) 2004-07-31 2011-03-16 Monsanto Technology LLC Genes and uses for plant improvement
EP3059306A1 (en) 2005-01-12 2016-08-24 Monsanto Technology LLC Genes and uses for plant improvement
EP2489726A2 (en) 2005-01-12 2012-08-22 Monsanto Technology LLC Genes and uses for plant improvement
EP2584033A1 (en) 2005-01-12 2013-04-24 Monsanto Technology LLC Genes and uses for plant improvement
WO2006133983A1 (en) 2005-04-19 2006-12-21 Basf Plant Science Gmbh Starchy-endosperm and/or germinating embryo-specific expression in mono-cotyledonous plants
EP2270181A2 (en) 2005-09-16 2011-01-05 deVGen N.V. DSRNA as insect control agent
EP2275563A2 (en) 2005-09-16 2011-01-19 deVGen N.V. Transgenic plant-based methods for plant insect pests using RNAi
US11939589B2 (en) 2005-09-16 2024-03-26 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
EP2269444A2 (en) 2005-09-16 2011-01-05 deVGen N.V. DSRNA as insect control agent
EP2270182A2 (en) 2005-09-16 2011-01-05 deVGen N.V. DSRNA as insect control agent
US11312975B2 (en) 2005-09-16 2022-04-26 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
EP2275562A2 (en) 2005-09-16 2011-01-19 deVGen N.V. Transgenic plant-based methods for plant insect pests using RNAi
US10538783B2 (en) 2005-09-16 2020-01-21 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
EP3173486A1 (en) 2005-09-16 2017-05-31 Monsanto Technology LLC Methods for genetic control of insect infestations in plants and compositions thereof
EP2281896A2 (en) 2005-09-16 2011-02-09 deVGen N.V. Transgenic plant-based methods for plant insect pests using RNAi
EP3508582A1 (en) 2005-09-16 2019-07-10 Monsanto Technology LLC Methods for genetic control of insect infestations in plants and compositions thereof
US9695439B2 (en) 2005-09-16 2017-07-04 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
EP2281876A2 (en) 2005-09-16 2011-02-09 deVGen N.V. Methods for controlling pests using RNAi
EP2295584A2 (en) 2005-09-16 2011-03-16 deVGen N.V. Transgenic plant-based methods for plant pests using RNAi
US8759611B2 (en) 2005-09-16 2014-06-24 Monsanto Technology Llc Methods for genetic control of insect infestation in plants and compositions thereof
US7943819B2 (en) 2005-09-16 2011-05-17 Monsanto Technology Llc Methods for genetic control of insect infestations in plants and compositions thereof
EP2330207A2 (en) 2005-09-16 2011-06-08 deVGen N.V. Transgenic plant-based methods for plant pests using RNAi
EP2426208A1 (en) 2005-09-16 2012-03-07 Monsanto Technology, LLC Methods for genetic control of insect infestations in plants and compositions thereof
EP2431473A1 (en) 2005-09-16 2012-03-21 Monsanto Technology LLC Methods for genetic control of insect infestations in plants and compositions thereof
EP2439278A1 (en) 2005-09-16 2012-04-11 Monsanto Technology LLC Methods for genetic control of insect infestations in plants and compositions thereof
EP2439279A1 (en) 2005-09-16 2012-04-11 Monsanto Technology LLC Methods for genetic control of insect infestations in plants and compositions thereof
WO2007095469A2 (en) 2006-02-10 2007-08-23 Monsanto Technology Llc Identification and use of target genes for control of plant parasitic nematodes
EP2426206A2 (en) 2006-02-13 2012-03-07 Monsanto Technology LLC Selecting and stablizing dsRNA constructs
US10941398B2 (en) 2006-02-13 2021-03-09 Monsanto Technology Llc Selecting and stabilizing dsRNA constructs
US11708577B2 (en) 2006-02-13 2023-07-25 Monsanto Technology Llc Modified gene silencing
US9765351B2 (en) 2006-02-13 2017-09-19 Monsanto Technology Llc Modified gene silencing
US8895805B2 (en) 2006-12-04 2014-11-25 Shanghai Institutes For Biological Sciences, Chinese Academy Of Sciences Method for modifying insect resistance of plants by utilizing RNAi technique
WO2008099013A1 (en) 2007-02-16 2008-08-21 Basf Plant Science Gmbh Nucleic acid sequences for regulation of embryo-specific expression in monocotyledonous plants
US8329989B2 (en) 2008-09-29 2012-12-11 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
US8692080B2 (en) 2008-09-29 2014-04-08 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
US10344292B2 (en) 2008-09-29 2019-07-09 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
US9572311B2 (en) 2008-09-29 2017-02-21 Monsanto Technology Llc Soybean transgenic event MON87705 and methods for detection thereof
WO2010123904A1 (en) 2009-04-20 2010-10-28 Monsanto Technology Llc Multiple virus resistance in plants
EP3260545A1 (en) 2009-04-20 2017-12-27 Monsanto Technology LLC Multiple virus resistance in plants
WO2012092544A2 (en) 2010-12-30 2012-07-05 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP3375878A1 (en) 2010-12-30 2018-09-19 Dow AgroSciences LLC Nucleic acid molecules that target the vacuolar atphase h subunit and confer resistance to coleopteran pests
EP3354735A1 (en) 2010-12-30 2018-08-01 Dow AgroSciences LLC Nucleic acid molecules that target the rho1 small gtp-binding protein and confer resistance to coleopteran pests
EP3339440A1 (en) 2010-12-30 2018-06-27 Dow AgroSciences LLC Nucleic acid molecules that target the vacuolar atpase c subunit and confer resistance to coleopteran pests
US9688983B2 (en) 2012-12-20 2017-06-27 Dow Agrosciences Llc Nucleic acid molecules that confer resistance to coleopteran pests
EP2810952A1 (en) 2013-06-03 2014-12-10 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel pest control methods
WO2015095750A1 (en) 2013-12-20 2015-06-25 Dow Agrosciences Llc Rnapii-140 nucleic acid molecules that confer resistance to coleopteran pests
WO2015095774A1 (en) 2013-12-20 2015-06-25 Dow Agrosciences Llc Ras opposite (rop) and related nucleic acid molecules that confer resistance to coleopteran and/or hemipteran pests
EP3719129A1 (en) 2014-03-12 2020-10-07 The University of Sydney Rna production in higher plants
WO2015171784A1 (en) 2014-05-07 2015-11-12 Dow Agrosciences Llc Dre4 nucleic acid molecules that confer resistance to coleopteran pests
EP3037432A1 (en) 2014-12-22 2016-06-29 Dow AgroSciences LLC Nucampholin nucleic acid molecules to control coleopteran insect pests
EP3067424A1 (en) 2015-03-13 2016-09-14 Dow AgroSciences LLC Rna polymerase i1 nucleic acid molecules to control insect pests
WO2016165729A1 (en) 2015-04-13 2016-10-20 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Novel aflatoxin and fungal infection control methods
WO2016196247A1 (en) 2015-05-29 2016-12-08 Dow Agrosciences Llc Spt5 nucleic acid molecules to control insect pests
US10344298B2 (en) 2015-10-12 2019-07-09 Dow Agrosciences Llc WUPA nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
US10329581B2 (en) 2015-12-18 2019-06-25 Dow Agrosciences Llc Ribosomal protein L40 (RPL40) nucleic acid molecules that confer resistance to coleopteran and hemipteran pests
WO2018089237A1 (en) 2016-11-10 2018-05-17 Dow Agrosciences Llc Cytochrome b (cytb) nucleic acid molecules that control pathogens
EP3342780A1 (en) 2016-12-30 2018-07-04 Dow AgroSciences LLC Pre-mrna processing factor 8 (prp8) nucleic acid molecules to control insect pests
WO2021099377A1 (en) 2019-11-19 2021-05-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control
EP3825408A1 (en) 2019-11-19 2021-05-26 FRAUNHOFER-GESELLSCHAFT zur Förderung der angewandten Forschung e.V. Methods of multi-species insect pest control

Also Published As

Publication number Publication date
EP0918853A2 (en) 1999-06-02
WO1998005770A3 (en) 1998-03-26
DE19631919A1 (en) 1998-02-12
DE19631919C2 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE19631919C2 (en) Anti-sense RNA with secondary structure
EP1798285B1 (en) Methods and medicament for inhibition the expression of a defined gene
DE69330162T2 (en) METHOD FOR THE SYNTHESIS OF COMPLETE cDNA, METHOD FOR PRODUCING INTERMEDIATES AND FOR PRODUCING A RECOMBINANT VECTOR CONTAINING THE COMPLETE cDNA
DE69232032T3 (en) ANTISENSE OLIGONUCLEOTIDE
EP0519463B1 (en) Synthetic, catalytic oligonucleotides
DE19935756A1 (en) Covalently closed nucleic acid molecule for immune stimulation
DE69228098T2 (en) Process for the synthesis of stable, single-stranded cDNA in eukaryotes by transfection with a vector containing bacterial &#34;retron&#34; and the vector used
DE69634698T2 (en) TISSUE SPECIFIC AND TARGET RNA SPECIFIC RIBOZYMES
EP0753580A2 (en) Cell-specific gene therapy, using the tissue inhibitor of metalloproteinase-3 promoter
DE69232768T2 (en) Single-stranded hybrid DNA-RNA molecules and methods of manufacture
DE69122246T2 (en) IDENTIFICATION OF NEW MEDICINES AND REAGENTS
EP0299303B1 (en) Eucaryotic expression vectors with multimeric enhancer subelements, process for their preparation and use
EP0345615A2 (en) Expression vectors for the production of non-fusion proteins in microorganisms
DE69022165T2 (en) Cloning plasmid vector, primer vector thereof and cDNA library production method.
DE4444949C1 (en) Vectors and viruses for gene therapy
DE69031080T2 (en) METHOD FOR PRODUCING CATALYTIC RNS IN BACTERIA
WO1998005771A1 (en) Method for increasing the effect of antisense rna in cells
DE69933382T2 (en) PREPARATION OF SSDNA INSIDE THE CELL
DE4422259C2 (en) Anti-sense oligonucleotides for aromatase inhibition
WO2002068636A1 (en) Methods and agents for modifying human angiogenesis
EP1149161A2 (en) Ribozymes directed against the catalytic subunit of the human telomerase (htert)
WO2001005993A1 (en) Cellular absorption of dna
DE3929822A1 (en) DNA vector including multiple cloning site - for cloning, specific mutagenesis, sequencing and optimised expression of inserted genes, and construction of gene banks

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1997936610

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09230930

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997936610

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998507488

Format of ref document f/p: F

WWW Wipo information: withdrawn in national office

Ref document number: 1997936610

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载